Comprehensive Tumor Profiling (DNA-RNA)

Comprehensive Tumor Profiling (DNA–RNA) is an advanced Next-Generation Sequencing (NGS)–based assay designed to provide a broad molecular characterization of solid tumors. The test simultaneously analyzes 562 cancer-related genes at the DNA level and 100 genes at the RNA level to detect multiple classes of genomic alterations that may drive tumor development, progression, and treatment response.

The DNA component of the assay identifies a wide spectrum of genomic variants, including single nucleotide variants (SNVs), small insertions and deletions (indels), copy number variations (CNVs), and structural alterations across key oncogenes and tumor suppressor genes. This analysis enables the detection of clinically relevant mutations that may be associated with targeted therapies, prognostic implications, or resistance mechanisms.

The RNA component focuses on the detection of gene fusions and rearrangements, which are important oncogenic drivers in many cancers. RNA sequencing allows for the identification of fusion transcripts involving critical genes such as ALK, ROS1, RET, NTRK, and others, which may not always be detected reliably at the DNA level. By analyzing gene expression and fusion events, RNA sequencing improves the overall sensitivity for detecting therapeutically actionable alterations.

By integrating both DNA and RNA analysis, Comprehensive Tumor Profiling offers a more complete understanding of the tumor’s molecular landscape compared with DNA-only testing. The results provide clinicians with valuable information regarding actionable biomarkers, eligibility for targeted therapies, potential immunotherapy markers, and suitability for relevant clinical trials.

This test is typically performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue, The comprehensive molecular insights generated by this test support precision oncology approaches, enabling more informed and personalized treatment strategies for cancer patients